However, primary AML cells treated with ara-C can undergo caspase-independent programmed cell death,10 and caspase-3 activation trends failed to predict ara-C and anthracycline drug sensitivity of primary AML isolates from 42 patients.17 This evidence concerns the gene CASP3 and acute myeloid leukemia.